This study assessed the efficacy of laxative use for treatment of constipation in patients receiving opioid therapy, with special attention to polyethylene glycol 3350/electrolyte solution (PEG-ES). Computerized data from 206 patients were analyzed using descriptive statistics. Subgroups were analyzed using confirmatory statistics. Constipation occurred in 42.7 percent of patients. Laxatives were administered to 74.3 percent of these patients using a standardized step scheme, with good results in 78.4 percent. As a therapy for constipation, the combined administration of PEG-ES, sodium picosulphate, and liquid paraffin proved most effective, although statistical analysis yielded no significance. Early use of PEG-ES using a step scheme holds promise for treatment of opioid-related constipation in palliative care patients, although further investigation is warranted.
Bruera E, Suarez-Almazor M, Velasco A, et al.: The assessment of constipation in terminal cancer patients admitted to a palliative care unit: A retrospective review. J Pain Symptom Manage. 1994; 9: 515-519.
2.
Ferguson A: Improving the management of constipation and faecal impaction. Geriatr Med. 1998; 6: 29-30.
Twycross RG, Lack SA: Control of alimentary symptoms in far advanced cancer. Edinburgh: Churchill Livingstone, 1986: 166-207.
5.
Sykes NP: The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998; 12(5): 375-382.
6.
Ferrer-Brechner T, Ganz P: Combination therapy with ibuprofen and methadone for chronic cancer pain. Am J Med. 1984; 77: 78-83.
7.
Grond S, Zech D, Diefenbach C, et al.: Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage. 1994; 9: 372-382.
8.
Reuben DB, Mor V, Hiris J: Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988; 148: 1586-1591.
9.
Sykes NP: A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom Manage. 1996; 11: 363-369.
10.
Sykes NP: Constipation and diarrhoea. In Doyle D, Hanke G, MacDonald N (eds.): Oxford Textbook of Palliative Medicine (2nd ed.). Oxford: Oxford University Press, 1999.
11.
Watanabe S, Belzile M, Kuehn N, et al.: Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: Clinical and economic considerations. Cancer Treat Rev. 1996; 22(Suppl A): 131-136.
12.
Holmes S: Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud. 1989; 26: 69-79.
13.
Schulzeck S, Gleim M, Maier C: Morphine tablets for chronic non-tumor-induced pain. Which factors modify the success or failure of a long-term therapy?Anaesthesist [German]. 1993; 42(8): 545-556.
14.
Twycross RG, Zenz M: Use of oral morphine in incurable pain. Anaesthesist[German]. 1983; 6: 279-283.
15.
Drossman DA, Sandler RS, McKee DC, et al.: Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology. 1982; 83: 529-534.
16.
Drossman DA, Thompson WG, Talley NJ, et al.: Identification of subgroups of functional gastrointestinal disorders. Gastroenterol Int. 1990; 3: 159-172.
17.
Sandler RS, Jordan MC, Shelton BJ: Demographic and dietary determinants of constipation in the US population. Am J Public Health. 1990; 80: 185-189.
18.
Fallon MT, Hanks GW: Morphine, constipation and performance status in advanced cancer patients. Palliat Med. 1999; 13: 159-160.
Pahor M, Mugelli A, Guralnik JM, et al.: Age and laxative use in hospitalized patients. A report of the Gruppo Italiano di Farmacovigilanza nell’Anziano (GIFA). Aging. 1995; 7: 128-135.
21.
Sykes NP: Current approaches to the management of constipation. Cancer Surv. 1994; 21: 137-146.
22.
Agra Y, Sacristan A, Gonzalez M, et al.: Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage. 1998; 15: 1-7.
23.
Ramesh PR, Kumar KS, Rajagopal MR, et al.: Managing morphine-induced constipation: A controlled comparison of an Ayurvedic formulation and senna. J Pain Symptom Manage. 1998; 16: 240-244.
24.
Daeninck PJ, Bruera E: Reduction in constipation and laxative requirements following opioid rotation to methadone: A report of four cases. J Pain Symptom Manage. 1999; 18: 303-309.
25.
Radbruch L, Sabatowski R, Loick G, et al.: Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000; 14: 111-119.
26.
Schoorl J, Zylicz Z: Laxative policy for terminal patients ineffective. Ned Tijdschr Geneeskd [The Netherlands]. 1997; 26: 823-826.
27.
MacLennan WJ, Pooler AFWM: A comparison of sodium picosulphate (“Laxoberal”) with standardised senna (“Sennokot”) in geriatric patients. Curr Med Res Opin. 1974-75; 2: 641-647.
28.
Culbert P, Gillett H, Ferguson A: Highly effective new oral therapy for faecal impaction. Br J Gen Pract. 1998; 48: 1599-1600.
29.
Ungar A: Movicol in treatment of constipation and faecal impaction. Hosp Med. 2000; 1: 37-40.
30.
Freedman MD, Schwartz HJ, Roby R, et al.: Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: A double-blinded placebo-controlled trial. J Clin Pharmacol. 1997; 37: 904-907.
31.
Dakkak M, Aziz K, Bennet JR: Short report: Comparison of two orally administered bowel preparations for colonoscopy—polyethylene glycol and sodium picosulphate. Aliment Pharmacol Ther. 1992; 6: 513-519.
